Durham, North Carolina-based Quintiles IMS Holdings Inc.'s stock finished Thursday's session 0.79% higher at $77.54. A total volume of 1.83 million shares was traded, which was above their three months average volume of 1.63 million shares. The Company's shares have advanced 2.11% in the past one month, 0.61% over the previous three months, and 12.93% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 1.11% and 8.05%, respectively. Furthermore, shares of Quintiles IMS Holdings, which provides biopharmaceutical development services and commercial outsourcing services in the Americas, Europe, Africa, and the Asia/Pacific, have a Relative Strength Index (RSI) of 50.99.
On December 2nd, 2016, research firm Bank of America/Merrill downgraded the Company's stock rating from 'Buy' to 'Neutral'. Free research report on Q is available at:
Shares in Waltham, Massachusetts headquartered PAREXEL International Corp. ended at $65.27, up 2.18% from the last trading session. The stock recorded a trading volume of 1.55 million shares, which was higher than its three months average volume of 746,310 shares. The Company's shares have gained 12.61% in the last one month. The stock is trading 4.68% above its 50-day moving average and 2.79% above its 200-day moving average. Moreover, shares of PAREXEL International, which provides clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology products and services for pharmaceutical, biotechnology, and medical device industries worldwide, have an RSI of 67.57.
On November 23rd, 2016, research firm Wells Fargo downgraded the Company's stock rating from 'Outperform' to 'Market Perform'. The complimentary research report on PRXL can be downloaded at:
Charles River Laboratories
Wilmington, Massachusetts headquartered Charles River Laboratories International Inc.'s stock ended yesterday's session 1.48% higher at $73.52 with a total trading volume of 401,888 shares. The Company's shares have advanced 1.97% in the past one month. The stock is trading 4.00% below its 50-day moving average. Additionally, shares of Charles River Laboratories International, which provides drug discovery and preclinical development services worldwide, have an RSI of 49.62.
On November 30th, 2016, research firm Barclays upgraded the Company's stock rating from 'Underweight' to 'Equal Weight'. The research firm also revised upwards its previous target price from $65 to $77. Visit us today and access our complete research report on CRL at:
PRA Health Sciences
At the close on Thursday, shares in Raleigh, North Carolina headquartered PRA Health Sciences Inc. recorded a trading volume of 343,823 shares. The stock finished 1.06% higher at $54.57. The Company's shares have gained 8.86% in the previous three months and 20.54% on an YTD basis. The stock is trading above its 200-day moving average by 12.31%. Furthermore, shares of PRA Health Sciences, which provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide, have an RSI of 50.37. Get free access to your research report on PRAH at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA